Ocular Therapeutix (OCUL) Competitors $9.36 -0.10 (-1.06%) Closing price 07/3/2025 01:45 PM EasternExtended Trading$9.62 +0.26 (+2.78%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OCUL vs. AXSM, AKRO, PCVX, ADMA, PTCT, RYTM, CYTK, KRYS, ZLAB, and ACADShould you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Zai Lab (ZLAB), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Ocular Therapeutix vs. Its Competitors Axsome Therapeutics Akero Therapeutics Vaxcyte ADMA Biologics PTC Therapeutics Rhythm Pharmaceuticals Cytokinetics Krystal Biotech Zai Lab ACADIA Pharmaceuticals Ocular Therapeutix (NASDAQ:OCUL) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings. Which has better earnings & valuation, OCUL or AXSM? Ocular Therapeutix has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M23.40-$193.51M-$1.15-8.14Axsome Therapeutics$385.69M13.45-$287.22M-$5.77-18.26 Which has more volatility & risk, OCUL or AXSM? Ocular Therapeutix has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Is OCUL or AXSM more profitable? Axsome Therapeutics has a net margin of -64.39% compared to Ocular Therapeutix's net margin of -323.09%. Ocular Therapeutix's return on equity of -59.92% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-323.09% -59.92% -41.98% Axsome Therapeutics -64.39%-272.80%-36.69% Does the media refer more to OCUL or AXSM? In the previous week, Axsome Therapeutics had 15 more articles in the media than Ocular Therapeutix. MarketBeat recorded 17 mentions for Axsome Therapeutics and 2 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.87 beat Axsome Therapeutics' score of 0.13 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate OCUL or AXSM? Ocular Therapeutix presently has a consensus price target of $17.33, indicating a potential upside of 85.19%. Axsome Therapeutics has a consensus price target of $172.33, indicating a potential upside of 63.57%. Given Ocular Therapeutix's higher probable upside, equities research analysts clearly believe Ocular Therapeutix is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 3.06 Do institutionals & insiders believe in OCUL or AXSM? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by insiders. Comparatively, 22.3% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryAxsome Therapeutics beats Ocular Therapeutix on 9 of the 17 factors compared between the two stocks. Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUL vs. The Competition Export to ExcelMetricOcular TherapeutixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.53B$2.43B$5.54B$9.05BDividend YieldN/A1.78%5.24%4.03%P/E Ratio-8.148.9827.4320.23Price / Sales23.40682.84420.98118.64Price / CashN/A158.5936.8958.07Price / Book4.664.588.045.67Net Income-$193.51M$31.34M$3.18B$249.13M7 Day Performance1.52%3.25%2.88%3.28%1 Month Performance10.64%7.08%3.69%5.56%1 Year Performance40.33%0.17%36.15%21.12% Ocular Therapeutix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCULOcular Therapeutix3.9451 of 5 stars$9.36-1.1%$17.33+85.2%+39.9%$1.53B$63.72M-8.14230AXSMAxsome Therapeutics4.7501 of 5 stars$101.65+1.0%$172.33+69.5%+31.3%$4.96B$385.69M-17.62380Trending NewsAnalyst ForecastAnalyst RevisionAKROAkero Therapeutics3.5634 of 5 stars$54.03-0.3%$82.50+52.7%+137.2%$4.32BN/A-27.7130Insider TradePCVXVaxcyte1.7986 of 5 stars$33.25+1.2%$136.50+310.5%-56.4%$4.24BN/A-8.33160News CoverageADMAADMA Biologics4.2038 of 5 stars$17.87+0.7%$27.67+54.8%+63.2%$4.24B$426.45M21.02530PTCTPTC Therapeutics4.315 of 5 stars$49.60-1.2%$65.00+31.0%+57.3%$3.98B$806.78M7.621,410Analyst RevisionRYTMRhythm Pharmaceuticals3.8116 of 5 stars$62.13+0.2%$76.62+23.3%+61.2%$3.94B$130.13M-22.11140News CoverageCYTKCytokinetics3.9446 of 5 stars$32.64+0.6%$70.92+117.3%-37.7%$3.87B$18.47M-6.17250KRYSKrystal Biotech4.5922 of 5 stars$137.92+4.1%$211.13+53.1%-19.5%$3.83B$290.52M33.15210News CoverageAnalyst RevisionHigh Trading VolumeZLABZai Lab3.4261 of 5 stars$36.01+4.2%$47.37+31.5%+111.6%$3.81B$398.99M-14.461,869Insider TradeAnalyst RevisionGap UpACADACADIA Pharmaceuticals4.6298 of 5 stars$22.48-1.0%$27.64+23.0%+34.4%$3.80B$957.80M16.41510 Related Companies and Tools Related Companies AXSM Competitors AKRO Competitors PCVX Competitors ADMA Competitors PTCT Competitors RYTM Competitors CYTK Competitors KRYS Competitors ZLAB Competitors ACAD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCUL) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
